Xiaowen Bi

Dr. Xiaowen Bi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MZMiao Zhang
Miao Zhang
XBXiaowen Bi
Xiaowen Bi
Heat shock proteins (Hsps) are a group of stress-induced proteins involved in protein folding and maturation. Based on their molecular weight, Hsps can be divided into six families: small Hsps, Hsp40, Hsp60, Hsp70, Hsp90, and large Hsps. In the process of breast cancer tumorigenesis, Hsps play a central role in regulating cell reactions and functions including proliferation, metastasis, and apoptosis. Moreover, some of the critical Hsps also regulate the fine balance between the protective and destructive immunological responses within the tumor microenvironment. In this review, we systematically summarize the roles of major Hsps in breast cancer biology and point out the potential uses of these proteins in breast cancer diagnosis and therapy. Understanding the roles of different families of Hsps in breast cancer pathogenesis will help in the development of more effective prevention and treatment measures for breast cancer.

6 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLixia Cheng
Lixia Cheng
ZHZhenghui Hu
Zhenghui Hu
JGJiawei Gu
Jiawei Gu
QLQian Li
Qian Li
JLJiahao Liu
Jiahao Liu
XBXiaowen Bi
Xiaowen Bi
As a fundamental process of innate immunity, inflammation is associated with the pathologic process of various diseases and constitutes a prevalent risk factor for both cancer and cardiovascular disease (CVD). Studies have indicated that several non-steroidal anti-inflammatory drugs (NSAIDs), including Meloxicam, may prevent tumorigenesis, reduce the risk of carcinogenesis, improve the efficacy of anticancer therapies, and reduce the risk of CVD, in addition to controlling the body’s inflammatory imbalances. Traditionally, most NSAIDs work by inhibiting cyclooxygenase (COX) activity, thereby blocking the synthesis of prostaglandins (PGs), which play a role in inflammation, cancer, and various cardiovascular conditions. However, long-term COX inhibition and reduced PGs synthesis can result in serious side effects. Recent studies have increasingly shown that some selective COX-2 inhibitors and NSAIDs, such as Meloxicam, may exert effects beyond COX inhibition. This emerging understanding prompts a re-evaluation of the mechanisms by which NSAIDs operate, suggesting that their benefits in cancer and CVD treatment may not solely depend on COX targeting. In this review, we will explore the potential COX-independent mechanisms of Meloxicam and other NSAIDs in addressing oncology and cardiovascular health.

4 March 2020 in Inflammation
Verified
Journal Article
Closed access
PDF file
XBXiaowen Bi
Xiaowen Bi
JLJinfei Li
Jinfei Li
XFXiRui Fan
XiRui Fan
JZJinyi Zhou
Jinyi Zhou
BJBaolin Jiang
Baolin Jiang
XBXiaowen Bi
Xiaowen Bi

13 April 2023 in Toxicology
Verified
Journal Article
Closed access
MZMiao Zhang
Miao Zhang
XBXiaowen Bi
Xiaowen Bi
SLShuai Liu
Shuai Liu
YLYu Liu
Yu Liu
QWQiyu Wang
Qiyu Wang

10 August 2024 in Toxicon
Verified
Journal Article
Closed access
JSJiaqi Sun
Jiaqi Sun
JLJiahao Liu
Jiahao Liu
MLMeiling Liu
Meiling Liu
XBXiaowen Bi
Xiaowen Bi
Chunhong HuangChunhong Huang
Chunhong Huang

12 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LCLixia Cheng
Lixia Cheng
QLQian Li
Qian Li
YLYuting Liu
Yuting Liu
JLJiahao Liu
Jiahao Liu
JZJianqi Zhao
Jianqi Zhao
Chunhong HuangChunhong Huang
Chunhong Huang
Background: Macrophage pyroptosis contributes substantially to sepsis-induced lung injury, yet effective therapeutic strategies remain limited. This study aimed to determine the protective effects of meloxicam, a non-steroidal anti-inflammatory drug, and the underlying mechanisms in this context. Methods:In vivo, CLP mice were treated with meloxicam (20 mg/kg). In vitro, LPS-primed macrophages were stimulated with ATP or nigericin in the presence or absence of meloxicam. Levels of pyroptosis-associated proteins (cleaved Caspase-1, mature IL-1β, GSDMD-NT), NLRP3 inflammasome assembly, and the CBP/TXNIP/p38 signaling axis were assessed by Western blot. Mitochondrial membrane potential (ΔΨm) and intracellular ROS were measured. Overexpression of COX-2, TXNIP, and CBP was also performed. Results: Meloxicam significantly improved survival, reduced lung injury, and suppressed pyroptosis-associated proteins in CLP mice. In vitro, meloxicam dose-dependently enhanced macrophage viability and reduced LDH, IL-1β, and IL-18 release. The protective effects of meloxicam were mediated by inhibition of NLRP3 inflammasome priming and assembly, disruption of NLRP3-ASC-pro-Caspase-1 complex formation, and suppression of ASC oligomerization. Meloxicam also inhibited the CBP/TXNIP/p38 axis, an effect reversed by TXNIP or CBP overexpression. Furthermore, meloxicam restored ΔΨm and reduced ROS accumulation; these effects were abrogated by the ROS inducer imiquimod. Importantly, the anti-pyroptotic effects of meloxicam were independent of COX-2 inhibition. Conclusions: These findings expand the pharmacological profile of meloxicam and support its repurposing as a therapeutic agent for sepsis-associated lung injury.